Andere talen NovoCure Limited

Aandelen

NVCR

JE00BYSS4X48

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
12,09 ^USD	+0,33%		-10,91%	-19,02%

10/04	NOVOCURE LIMITED : Piper Sandler ontvangt een koopadvies	ZM
05/04	NovoCure zegt dat nieuwe gegevens de potentiële therapeutische effecten van TTFields bij alvleesklierkanker aantonen	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research Annual Meeting 2024	08/04
NovoCure Says New Data Show TTFields' Potential Therapeutic Effects in Pancreatic Cancer	05/04
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024	05/04
Novocure to Report First Quarter 2024 Financial Results	01/04
Klinische Phase-3-Studie METIS erreicht primären Endpunkt und zeigt eine statistisch signifikante Verlängerung der Zeit bis zur intrakraniellen Progression bei Patient:innen mit Hirnmetastasen von nicht-kleinzelligem Lungenkrebs	28/03
L’essai clinique de phase 3 METIS a atteint son critère principal, démontrant un allongement statistiquement significatif du délai médian jusqu’à la progression intracrânienne chez les patients porteurs de métastases cérébrales consécutives...	28/03
Novocure - METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer	28/03
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases	28/03
Aktien New York Schluss: Anleger greifen nach Rücksetzer wieder zu	27/03
Zai Lab, Novocure Say TTFields Therapy Delays Intracranial Progression in Non-Small Cell Lung Cancer Brain Metastases Patients	27/03
Sector Update: Health Care Stocks Edge Higher Pre-Bell Wednesday	27/03
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	27/03
Sector Update: Health Care	27/03
NovoCure Says Trial of Therapy for Brain Metastases From Lung Cancer Met Primary Endpoint; Shares Jump Pre-Bell	27/03
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Board Governor Waller's Speech	27/03
Novocure's lung cancer therapy succeeds in late-stage trial	27/03
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer	27/03
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO	11/03
Novocure Q4 Net Loss Widens, Revenue Rises	22/02
NovoCure: Q4 Earnings Snapshot	22/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen NovoCure Limited

Aandelen

NVCR

JE00BYSS4X48

Andere talen

Filters